Research programme: small molecules therapeutics - Fulcrum Therapeutics
Latest Information Update: 10 Feb 2023
Price :
$50 *
At a glance
- Originator Fulcrum Therapeutics
- Class Small molecules
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Blood dyscrasias; Musculoskeletal disorders; Neurological disorders
- Discontinued Fragile X syndrome
Most Recent Events
- 09 Feb 2023 Preclinical trials in Neurological disorders in USA (unspecified route) as of February 2023 (Fulcrum Therapeutics pipeline, February 2023)
- 08 Feb 2023 Preclinical trials in Blood dyscrasias in USA (unspecified route) as of February 2023 (Fulcrum Therapeutics pipeline, February 2023)
- 08 Feb 2023 Preclinical trials in Musculoskeletal disorders in USA (unspecified route) as of February 2023 (Fulcrum Therapeutics pipeline, February 2023)